SCHEMBL2177700

SCHEMBL2177700

COCCCOc1cc(CCc2ccc(F)cc2F)cc(C(=O)Nc2nccs2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 8/20 0.51
RAB9A P51151 6/20 0.47
NPC1 O15118 5/20 0.47
MGAM O43451 1/20 0.46
GAA P10253 1/20 0.46
SI P14410 1/20 0.46
MGAM2 Q2M2H8 1/20 0.46
ALDH1A1 P00352 3/20 0.46
HSD17B10 Q99714 1/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
HPGD P15428 3/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
KCNH2 Q12809 1/20 0.44
LMNA P02545 1/20 0.43
BRD4 O60885 1/20 0.43
MAPT P10636 1/20 0.43
TP53 P04637 1/20 0.43
ALOX15 P16050 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2178409 0.93 GCK (0.49) GCKRAB9ANPC1MGAMGAA
SCHEMBL2178979 0.90 GCK (0.51) GCKRAB9ANPC1MGAMGAA
SCHEMBL2177705 0.88 GCK (0.67) GCKKCNH2
SCHEMBL2178805 0.86 GCK (0.51) GCKRAB9ANPC1MGAMGAA
SCHEMBL2178574 0.85 MAPT (0.49) GCKRAB9ANPC1ALDH1A1HSD17B10
SCHEMBL2176615 0.85 SMN1; SMN2 (0.51) GCKRAB9ANPC1ALDH1A1HSD17B10
SCHEMBL2180022 0.83 RAB9A (0.48) GCKRAB9ANPC1GAAALDH1A1
SCHEMBL2178466 0.83 KCNK3 (0.48) GCKRAB9ANPC1ALDH1A1HSD17B10
SCHEMBL2176271 0.83 SMN1; SMN2 (0.53) GCKRAB9ANPC1GAAALDH1A1
SCHEMBL2179784 0.83 SMN1; SMN2 (0.54) GCKRAB9ANPC1ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178765-A1 NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2012-07-12 US claimed
WO-2011081280-A2 NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2011-07-07 WO claimed
US-20120178765-A1 NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2012-07-12 US disclosed
WO-2011081280-A2 NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178765-A1 NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF GCK, GCKR, HK1 GCK 1/4885RAB9A 3743/4885NPC1 3351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.